Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543638 | 0.98 | CYP1A2 (0.45) | CYP1A2SIGMAR1EPHX1SMN1; SMN2HPGD | |
| SCHEMBL5541873 | 0.98 | CYP1A2 (0.45) | CYP1A2SIGMAR1EPHX1SMN1; SMN2HPGD | |
| SCHEMBL3258085 | 0.98 | CYP1A2 (0.45) | CYP1A2SIGMAR1EPHX1SMN1; SMN2HPGD | |
| SCHEMBL5545361 | 0.96 | CYP1A2 (0.37) | CYP1A2SIGMAR1EPHX1SMN1; SMN2HPGD | |
| SCHEMBL2191205 | 0.94 | EPHX1 (0.45) | CYP1A2SIGMAR1EPHX1HPGDNAAA | |
| SCHEMBL3031792 | 0.92 | EPHX1 (0.47) | CYP1A2SIGMAR1EPHX1HPGDNAAA | |
| SCHEMBL5546608 | 0.91 | — | — | |
| SCHEMBL5535569 | 0.90 | SIGMAR1 (0.48) | CYP1A2SIGMAR1EPHX1HPGDNAAA | |
| SCHEMBL5547911 | 0.90 | SIGMAR1 (0.48) | CYP1A2SIGMAR1EPHX1HPGDNAAA | |
| SCHEMBL5535372 | 0.89 | EPHX1 (0.41) | CYP1A2SIGMAR1EPHX1HPGDNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-1745002-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1745002-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2005105725-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2001002413-A1 | BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY | INSTITUTO BIOMAR S.A. (ES) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP1A2 659/4885SIGMAR1 234/4885EPHX1 4071/4885 |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | CYP1A2 299/4885SIGMAR1 664/4885EPHX1 1901/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | CYP1A2 1651/4885SIGMAR1 1441/4885EPHX1 2037/4885 |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | PPARG, PPARD, GPR119 | CYP1A2 582/4885SIGMAR1 1164/4885EPHX1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.